# AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

> **NCT04413201** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Michael Hopp** · enrollment: 34 (actual)

## Conditions studied

- Non-squamous NSCLC

## Interventions

- **DRUG:** Afatinib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT04413201
- **Lead sponsor:** Michael Hopp
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04413201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04413201, "AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04413201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*